N,6-O-Disulfo-D-glucosamine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N,6-O-Disulfo-D-glucosamine
• 英文别名: [(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid
• 化学式: C₆H₁₃NO₁₁S₂
• 分子量: 339.3
• InChiKey: DQTRACMFIGDHSN-IVMDWMLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  217
• 氢给体数：
  6
• 氢受体数：
  12

文献信息

• Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
  申请人：Corning Incorporated

  公开号：EP2805930A1

  公开（公告）日：2014-11-26

  The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LYXUMIA (lixisenatide), LEMTRADA (alemtuzumab), REGN727/SAR236553 (alirocumab), SAR2405550/BSI-201 (iniparib), OTAMIXABAN (otamixaban), SARILUMAB (sarilumab), LANTUS and LYXUMIA (insulin glargine and lixisenatide) or VISAMERIN/MULSEVO (semuloparin sodium).

  本发明至少部分是基于对至少部分由玻璃组合物形成的药用容器的鉴定，这种玻璃组合物显示出较低的分层倾向，即较低的玻璃微粒脱落倾向。因此，本发明的容器特别适用于储存药物组合物，特别是包含药物活性成分的药液，例如 LYXUMIA（利西那肽）、LEMTRADA（阿来珠单抗）、REGN727/SAR236553（阿利珠单抗）、SAR2405550/BSI-201（依尼帕利布）、OTAMIXABAN（奥他米沙班）、SARILUMAB（沙利单抗）、LANTUS 和 LYXUMIA（格列酮胰岛素和利塞那肽）或 VISAMERIN/MULSEVO（SEa href=https://www.molaid.com/MS_76874 target="_blank">EMuloparin sodium）。
• Method for the analysis of glycosaminoglycans, and their derivatives and salts by nuclear magnetic resonance
  申请人：LABORATORIOS FARMACEUTICOS ROVI, S.A.

  公开号：US10705037B2

  公开（公告）日：2020-07-07

  An analytical method employing nuclear magnetic resonance of glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, is provided. The method is used for identification and the relative quantification of characteristic signals by 1H-NMR and/or 1H-13C HSQC.

  本研究提供了一种利用核磁共振对一般糖胺聚糖，特别是肝素和低分子量肝素及其衍生物进行分析的方法。该方法通过 1H-NMR 和/或 1H-13C HSQC 对特征信号进行识别和相对定量。
• HEPARIN CHROMATOGRAPHY OF ERYTHROPOIETINS
  申请人：HOECHST MARION ROUSSEL, INC.

  公开号：EP0862581A1

  公开（公告）日：1998-09-09
• US20140341891A1
  申请人：——

  公开号：US20140341891A1

  公开（公告）日：2014-11-20
• Method for the Analysis of Glycosaminoglycans, and Their Derivatives and Salts by Nuclear Magnetic Resonance
  申请人：LABORATORIOS FARMACEUTICOS ROVI, S.A.

  公开号：US20190154601A1

  公开（公告）日：2019-05-23

  The present invention describes an analytical method by nuclear magnetic resonance of glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, which allows their identification and the relative quantification of its characteristic signals by 1 H-NMR and/or 1 H- 13 C HSQC.